

# BBS-Bioactive Bone Substitutes Plc plans a share issue to strengthen its equity and will advance the publication date of its half-year report

BBS-Bioactive Bone Substitutes Plc | Company Release | June 18, 2024 at 08:00:00 EEST

## **BBS-Bioactive Bone Substitutes Plc plans a share issue to strengthen its equity and will advance the publication date of its half-year report**

The Annual General Meeting of BBS-Bioactive Bone Substitutes Plc on June 13, 2024, resolved to authorize the Board of Directors to decide on share issues and the issuance of option rights and other special rights entitling to shares as referred to in Chapter 10, Section 1 of the Finnish Companies Act, in one or more tranches. The number of shares to be issued under the authorization may total a maximum of 11,000,000 shares.

The decisions of the Annual General Meeting, including the authorizations for the share issue, can be read in full in the company release published on June 13, 2024.

Based on the authorizations given by the Annual General Meeting, the company is starting preparations for a share issue to increase its equity. The funds raised in the planned share issue are intended to be used, among other things, to complete the CE marking process of ARTEBONE® Paste, initiate the commercial phase, and ramp up production.

In connection with the planned share issue, the company has decided to bring forward the publication of the half-year report so that it will be published on August 9, 2024, instead of the previously announced August 30, 2024.

BBS-Bioactive Bone Substitutes Plc  
Board of Directors

### **For more information, please contact:**

Juliusz Rakowski, CEO  
+358 50 448 5132  
[juliusz.rakowski@bbs-artebone.fi](mailto:juliusz.rakowski@bbs-artebone.fi)

### **Certified Advisor:**

Nordic Certified Adviser AB,  
+46 70 551 67 29,  
[info@certifiedadviser.se](mailto:info@certifiedadviser.se)

### **Distribution**

Nasdaq Helsinki  
<https://www.bbs-artebone.fi/>



Company Release  
18 June 2024 08:00:00 EEST

### **BBS in brief**

*BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.*

*BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.*

*More information: [www.bbs-artebone.fi](http://www.bbs-artebone.fi)*